James Hassard - 10 Mar 2022 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role
Chief Commercial Officer
Signature
/s/ Marc Wilson, as attorney-in-fact
Issuer symbol
CRNX
Transactions as of
10 Mar 2022
Net transactions value
$0
Form type
4
Filing time
10 Mar 2022, 15:51:04 UTC
Previous filing
09 Mar 2022
Next filing
03 Mar 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRNX Stock Option (right to buy) Award $0 +160,000 $0.000000 160,000 10 Mar 2022 Common Stock 160,000 $19.73 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option is exercisable as follows: 25% of the shares subject to the option vest on February 28, 2023, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.